iSpecimenISPC
ISPC
About: iSpecimen Inc is a technology-driven company focused on connecting life science researchers who need human biofluids, solid tissues, and hematopoietic stem and immune cells for their research, with the available biospecimens. The company generates revenue by procuring various specimens from hospitals, laboratories, and other supply sites. Geographically, it has a presence in the Americas; Europe, the Middle East, Africa, and Asia Pacific, which majority, comes from the Americas.
Employees: 24
0
Funds holding %
of 7,327 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
14% more funds holding
Funds holding: 7 [Q4 2024] → 8 (+1) [Q1 2025]
2.53% more ownership
Funds ownership: 3.72% [Q4 2024] → 6.26% (+2.53%) [Q1 2025]
33% less capital invested
Capital invested by funds: $94.9K [Q4 2024] → $63.7K (-$31.2K) [Q1 2025]
Research analyst outlook
We haven’t received any recent analyst ratings for ISPC.
Financial journalist opinion
Based on 5 articles about ISPC published over the past 30 days
Neutral
GlobeNewsWire
1 day ago
iSpecimen Inc. Announces Pricing of Approximately $1.75 Million Private Placement Priced At-the-Market
WOBURN, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, today announced that it entered into a securities purchase agreement with accredited investors for aggregate gross proceeds of approximately $1.75 million, before deducting fees to the placement agent and other offering expenses payable by the Company. The Company intends to use the net proceeds from the offering to pay $500,000 for marketing and advertising services to be provided by IR Agency LLC, and the remainder for working capital and general corporate purposes.
Neutral
GlobeNewsWire
4 days ago
Correction: iSpecimen Inc. Announces Closing of $4 Million Underwritten Offering
WOBURN, Mass., July 28, 2025 (GLOBE NEWSWIRE) -- This press release corrects a version issued on July 25, 2025 that incorrectly listed KCSA Strategic Communications as iSpecimen's investor relations contact. KCSA is not currently affiliated with iSpecimen Inc. and was mistakenly included in the prior release. The corrected release is below in its entirety.
Neutral
GlobeNewsWire
4 days ago
Correction: iSpecimen Inc. Announces Pricing of $4 Million Underwritten Offering
WOBURN, Mass., July 28, 2025 (GLOBE NEWSWIRE) -- This press release corrects the version issued on July 24, 2025 that incorrectly listed KCSA Strategic Communications as iSpecimen's investor relations contact. KCSA is not currently affiliated with iSpecimen Inc. and was mistakenly included in the prior release. The corrected release is below in its entirety.
Neutral
GlobeNewsWire
1 week ago
iSpecimen Inc. Announces Closing of $4 Million Underwritten Offering
WOBURN, Mass., July 25, 2025 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, announced today the closing of its previously announced underwritten public offering of 5,714,283 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) at a public offering price of $0.70 per share (the “Offering”). The aggregate gross proceeds to the Company from the Offering was approximately $4 million, before deducting underwriting discounts and commissions and other offering expenses.
Neutral
GlobeNewsWire
1 week ago
iSpecimen Inc. Announces Pricing of $4 Million Underwritten Offering
WOBURN, Mass., July 24, 2025 (GLOBE NEWSWIRE) -- iSpecimen Inc.
Neutral
Newsfile Corp
6 months ago
iSpecimen Secures Suppliers for COVID-style hMPV Outbreak
Woburn, Massachusetts--(Newsfile Corp. - January 16, 2025) - iSpecimen Inc. (NASDAQ: ISPC), a leading online marketplace for human biospecimens, has secured suppliers for the flu-like human metapneumovirus (hMPV). The virus has been causing hospitals in China to become overrun, raising the potential for another COVID-style pandemic.
Neutral
Newsfile Corp
7 months ago
iSpecimen Will Serve as a Preferred Provider of Cancer Biospecimens
Woburn, Massachusetts--(Newsfile Corp. - December 20, 2024) - iSpecimen Inc. (NASDAQ: ISPC), a leading online marketplace for human biospecimens, today announced its strategic initiatives for 2025, expanding services to procure high demand cancer biospecimens, enhancing its ability to support groundbreaking cancer research worldwide. The demand for cancer tissue continues to grow as cancer remains a significant area of focus in medical research and investment.
Neutral
Newsfile Corp
7 months ago
iSpecimen Reports Positive Results on Next Day Quote Program for Researchers and Providers
Woburn, Massachusetts--(Newsfile Corp. - December 13, 2024) - iSpecimen Inc. (NASDAQ: ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, announced today positive results attributed to its Next Day Quote Program ("NDQ"). This next-day quote service for researchers and providers is tailored to accelerate the biospecimen transaction process and delivers accurate biospecimen sample pricing within 24 hours of receiving the customer request.
Neutral
Newsfile Corp
7 months ago
iSpecimen Appoints Robert Lim as CEO and Director
Woburn, Massachusetts--(Newsfile Corp. - December 12, 2024) - iSpecimen Inc. (NASDAQ: ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, announced today that it has appointed Robert Lim as CEO and director. Mr. Lim is the principal and co-founder of De Novo Law Corporation, a Vancouver-based law firm specializing in corporate/commercial law and civil litigation.
Neutral
Newsfile Corp
8 months ago
iSpecimen Named Top Competitor in $4.4 Billion USD Market
Biospecimen Market To Exceed $13.5 Billion USD By 2032 Woburn, Massachusetts--(Newsfile Corp. - November 8, 2024) - iSpecimen Inc. (NASDAQ: ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, announced today the addressable Biospecimen contract research services market is attractive and growing. In fact, according to AceInsight Analytic, the market is presently valued at USD 4.4 billion as of 2023 and is predicted to reach USD 13.5 billion by the year 2032, growing at a 13.3% CAGR during the forecast period.
Charts implemented using Lightweight Charts™